Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

By S. Dawood, K. Broglio, A. Buzdar, G. Hortobagyi, S. Giordano. Journal of Clinical Oncology, 2010

793 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010, background): “Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), significantly improves survival in patients with HER2-positive breast cancer in both the metastatic(1-3) and adjuvant settings.(4-9) However, despite this notable success, there is still a need to improve H”
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer (2013, background): “High HER2 expression was first a marker of worse survival, but the introduction of targeted anti-HER2 therapy changed the picture: today HER2 positive patients have an improved prognosis compared to women with HER2 negative disease [27].”
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011, background): “receptor 2 (HER2) occurs in 15% to 25% of all breast cancers and is associated with poor prognosis.(1,2) The”
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2012, background): “Biologic agent other than trastuzumab or pertuzumab 21 (4) 13 (3)”